Observational Study

Endoscopic score predicting recurrence after foam sclerotherapy in grade I internal hemorrhoids: Development and external validation

Fei-Yu Zhang *et al*. Endo-HRS for hemorrhoids recurrence

Fei-Yu Zhang[1*], Lei-Ming Xu[1*], Feng-Yu Gao[2], Wen Wang[3], Wu-Lian Lin[3], Hao Zhang[4], Ke-Zhou Wang[5], Qing-Jing Wang[1,6], Ao-Jia Jin[1], Ru-Ping Yang[1], Chun-Ying Qu[1], Yi Zhang[1], Zheng-Hong Li[1], Dou Wang[7], Cui-Cui Shi[1], Tian-Ben Shen[1], Fei Shen[1], Ye Hu[1†], Feng Shen[1,7†]

Fei-Yu Zhang, Lei-Ming Xu, Qing-Jing Wang, Ao-Jia Jin, Ru-Ping Yang, Chun-Ying Qu, Yi Zhang, Zheng-Hong Li, Cui-Cui Shi, Tian-Ben Shen, Fei Shen, Ye Hu, Feng Shen, Department of Gastroenterology & Endoscopy, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Feng-Yu Gao, Department of Endoscopy, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan 250014, Shandong Province, China

Wen Wang, Wu-Lian Lin, Department of Gastroenterology, The 900th Hospital of the People's Liberation Army Joint Service Support Force, Fuzhou 350025, Fujian Province, China

Hao Zhang, Department of Endoscopy, Baoshan People's Hospital of Yunnan Province, Baoshan 678000, Yunnan Province, China

Ke-Zhou Wang, Department of Pathology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Qing-Jing Wang, Department of Gastroenterology, Jinshan Hospital of Fudan University, Shanghai 201508, China

Dou Wang, Department of gastroenterology, Shigatse People's Hospital, Shigatse 857000, Tibet Autonomous Region, China

Co-first Authors: Fei-Yu Zhang and Lei-ming Xu

Co-corresponding Authors: Ye Hu and Feng Shen

Author contributions: Fei-Yu Zhang and Lei-Ming Xu contributed equally to this work; Fei-Yu Zhang, Lei-Ming Xu, Ye Hu, and Feng Shen conceived and designed the study; Feng-Yu Gao, Wen Wang, Wu-Lian Lin, Hao Zhang, Qing-Jing Wang, Ao-Jia Jin, Ru-Ping Yang, Chun-Ying Qu, Yi Zhang, Zheng-Hong Li, Dou Wang, Cui-Cui Shi, Tian-Ben Shen, and Fei Shen collected clinical, endoscopic, and follow-up data; Ke-Zhou Wang performed the pathological assessment; Fei-Yu Zhang and Lei-Ming Xu analyzed the data and drafted the manuscript; Ye Hu and Feng Shen supervised the study and critically revised the manuscript; all authors interpreted the data, approved the final manuscript, and agree to be accountable for all aspects of the work.

Supported by the Discipline Peak-Climbing Plan of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. XKPF2024B404; the Shanghai Science and Technology Commission Innovation Ecosystem Construction Plan 'Domestic Science and Technology Cooperation' Project, No. 25010702300; and the National Natural Science Foundation of China, No. 82472899.

Corresponding Authors: Ye Hu, MD, PhD, Department of Gastroenterology & Endoscopy, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Rd, Shanghai 200092, China. E-mail: huye@xinhuamed.com.cn.

Feng Shen, Chief Physician, MD, Department of Gastroenterology & Endoscopy, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Road, Shanghai 200092, China. shenfeng01@xinhuamed.com.cn

Clinical trial registration statement: This study was prospectively registered at ClinicalTrials.gov (NCT04398823).

Biostatistics statement: The statistical methods of this study were reviewed by biomedical statisticians from the Clinical Research Unit of Xinhua Hospital.

TRIPOD statement: The authors have read the TRIPOD Statement, and the manuscript was prepared and revised according to the TRIPOD recommendations for development and external validation of a prognostic prediction model.

ORCID number: Ye Hu, 0000-0002-5093-6777. Feng Shen, 0000-0002-0066-980X.

Abstract

BACKGROUND

Foam sclerotherapy is an effective minimally invasive treatment for grade I internal hemorrhoids, but recurrence limits long-term benefit and no validated endoscopic tool is available for individualized risk prediction.

AIM

To develop and externally validate an endoscopy-based score for predicting recurrence after foam sclerotherapy in patients with grade I internal hemorrhoids.

METHODS

In this prospective, multicenter, observational cohort study, consecutive patients with grade I internal hemorrhoids who underwent 1% polidocanol foam sclerotherapy were enrolled. Candidate clinical and endoscopic variables were evaluated using Cox regression to construct a recurrence model. Model discrimination and calibration were assessed using Harrell's C-index, time-dependent receiver operating characteristic analysis, and bootstrap calibration. External validation was performed in an independent cohort, and a separate multimodal cohort was used for endoscopic and histopathological verification.

RESULTS

A total of 483 patients were included in model development, and 115 developed recurrence during follow-up. Kaplan-Meier estimates showed cumulative recurrence rates of 10.1% at 24 months and 20.0% at 36 months. Number of hemorrhoids, maximum hemorrhoid diameter, red color sign grade, and sex were retained in the final model to form the Endoscopic Hemorrhoid Recurrence Score (Endo-HRS). The model showed good discrimination in the development cohort (C-index 0.82; 36-month area under the curve 0.86) and strong external validity in an independent cohort of 279 patients (bootstrap-corrected C-index 0.90, 95%CI: 0.862-0.933). Endoscopic and histopathological findings were consistent with higher Endo-HRS categories.

CONCLUSION

Endo-HRS is a practical endoscopy-based score for predicting recurrence after foam sclerotherapy in grade I internal hemorrhoids. The model may support individualized surveillance and retreatment planning.

Key words: Grade I internal hemorrhoids; Foam sclerotherapy; Recurrence; Prediction model; Endoscopy

Core Tip: In this prospective multicenter observational study, we developed and externally validated Endo-HRS, a simple endoscopy-based score for predicting recurrence after 1% polidocanol foam sclerotherapy in grade I internal hemorrhoids. The score integrates sex, number of hemorrhoids, maximum hemorrhoid diameter, and red color sign grade, achieved strong discrimination in both development and external validation cohorts, and was biologically supported by endoscopic and histopathological verification. Endo-HRS may help tailor surveillance and retreatment after endoscopic therapy.

INTRODUCTION

Internal hemorrhoids, characterized by symptomatic enlargement or distal displacement of the anal vascular cushions, are among the most common anorectal disorders. The main clinical manifestations are bleeding, prolapse, and discomfort[1-2]. Available treatments range from conservative measures to definitive surgical intervention[3-4]. Among minimally invasive options, endoscopic foam sclerotherapy with polidocanol has attracted growing interest because of its procedural simplicity, rapid recovery, and favorable safety profile[5-7]. However, recurrence remains a major limitation[8-9], and currently available clinical grading systems do not provide a robust framework for individualized recurrence prediction.

Endoscopic polidocanol-based therapies have recently emerged as effective minimally invasive approaches for internal hemorrhoids. A multicenter randomized study demonstrated favorable efficacy and safety, with rapid recovery and low complication rates[10-12]. Nevertheless, recurrence after treatment remains an unresolved problem, and reliable tools for individualized risk stratification are lacking.

Therefore, we conducted a prospective multicenter observational study to develop and externally validate a novel endoscopic model for predicting recurrence after foam sclerotherapy in patients with grade I internal hemorrhoids.

MATERIALS AND METHODS

Study design and population

A prospective, multicenter, observational cohort study was conducted to develop and externally validate an endoscopic prediction model for recurrence after foam sclerotherapy for grade I internal hemorrhoids, in line with the TRIPOD reporting framework[13]. Consecutive patients were enrolled between January 2018 and December 2022 at four tertiary gastroenterology and endoscopy centers in China: Xinhua Hospital, Shandong Provincial Maternal and Child Health Care Hospital, the 900th Hospital of the PLA Joint Service Support Force, and Baoshan People's Hospital.

The target sample size was determined according to the expected number of recurrence events required for multivariable time-to-event modeling. Assuming a 3-year recurrence rate of approximately 20%-30%, a target enrollment exceeding 400 patients was prespecified.

Eligible participants were adults (18-70 yrs) with endoscopically confirmed Goligher grade I internal hemorrhoids who underwent 1% (20 mg/2 mL) polidocanol (Aethoxysklerol; Hameln Pharmaceuticals, Germany) foam sclerotherapy. Key exclusion criteria included advanced hemorrhoids, concomitant anorectal disease, contraindications to sclerotherapy, and other protocol-defined ineligibility criteria. Detailed inclusion and exclusion criteria are provided in *Supplementary Tables S1 and S2*. All participants provided written informed consent in accordance with the Declaration of Helsinki[14]. The study was prospectively registered at ClinicalTrials.gov (NCT04398823).

Endoscopic therapy and data collection

Patients followed a low-fiber diet on the day before colonoscopy and underwent split-dose bowel preparation with polyethylene glycol solution (Hengkangzhengqing; Hygecon, Shangrao, Jiangxi, China) according to ESGE recommendations[15]. Foam sclerotherapy was performed using a standardized technique[10]. Specifically, 1% polidocanol was prepared using Tessari's method[16] and injected through a 25-gauge InterjectTM needle (Boston Scientific, Marlborough, MA, United States) under endoscopic visualization (H290 series, Olympus, Tokyo, Japan).

Two experienced endoscopists, trained according to a standardized protocol, independently recorded the prespecified endoscopic variables. These variables included number of hemorrhoids, maximum hemorrhoid diameter, grade of red color sign, mucosal erosion, and degree of dentate line injury. The evaluators were blinded to the operators who performed the procedures, and discrepancies were resolved by consensus.

The number of hemorrhoids was confirmed using both antegrade and retroflexed views. Hemorrhoid diameter was measured with an endoscopic scale marker. The red color sign was graded from 0 to 3 according to the severity of vascular congestion: 0, absent; 1, scattered red dots on the hemorrhoid surface; 2, linear red streaks on the surface; and 3, a large area of confluent congestion (*Supplementary Figure S1*). Mucosal erosion was recorded as present or absent. Dentate line injury was classified as 0 (none), 1 (injury < 0.5 cm), or 2 (injury >= 0.5 cm).

Follow-up and outcomes

All patients underwent a minimum follow-up of 6 months, with scheduled clinic visits at 3-month intervals. Each visit included a clinical interview, digital rectal examination, and standardized questionnaire assessment (*Supplementary Table S3*). Patients also underwent protocolized surveillance colonoscopy every 6 months irrespective of symptoms. Endoscopic confirmation was mandatory for suspected recurrence, and all re-examination records were collected prospectively.

Follow-up was extended to 36 months in patients without recurrence and was terminated at the time of confirmed relapse. Recurrence was defined as the endoscopically confirmed reappearance of internal hemorrhoids associated with bleeding or definitive mucosal vascular abnormalities, whether detected during scheduled surveillance or prompted by symptoms. Time to recurrence was recorded in months.

Model development

Candidate predictors were first screened using univariable Cox proportional hazards regression. Variables with $P < 0.10$ were retained for multivariable analysis. The final model was derived by backward stepwise selection while considering clinical relevance in variable retention. The proportional hazards assumption was assessed using Schoenfeld residuals, and hazard ratios (HRs) with 95%CIs are reported.

The Endoscopic Hemorrhoid Recurrence Score (Endo-HRS) was created by assigning weighted points to each independent predictor according to the corresponding regression coefficient. Model discrimination was assessed using Harrell's concordance index (C-index) and time-dependent receiver operating characteristic curves. Calibration was evaluated using calibration plots. Internal validation was performed with 1000 bootstrap resamples to estimate optimism and adjust performance.
Patients were subsequently stratified into Endo-HRS groups A, B, and C according to Youden-optimized cutoffs, and recurrence-free interval among groups was compared using Kaplan-Meier analysis.

Web-based Endo-HRS calculator

A web-based Endo-HRS calculator was implemented to generate the weighted Endo-HRS score and classify patients into Endo-HRS groups A (low risk), B (moderate risk), and C (high risk) according to predefined cutoffs. The calculator is available at: *https://feiyuzhang.shinyapps.io/EndoHRS-Calculator/*.

External cohort validation of the Endo-HRS model

External validation was conducted in an independent cohort enrolled from separate clinical centers between January and December 2022 using the same predictor definitions and analytical strategy. No data from this cohort were used in model development.
The original Cox model was applied to the external cohort without refitting. Individual linear predictors and risks were calculated using the regression coefficients derived from the development cohort. Discrimination was evaluated with the C-index (95%CI obtained through 1000 bootstrap resamples) and time-dependent ROC analysis at 24, 36, and 48 months. Calibration was assessed by comparing predicted and observed 36-month recurrence probabilities using grouped calibration plots and a logit-LOESS smoothing approach.

Multi-modal verification of the Endo-HRS model

A separate multimodal verification cohort comprising endoscopic and histopathological images was obtained from participants who were not included in the development or external validation cohorts. During treatment, both antegrade and retroflexed endoscopic views were acquired. Two blinded endoscopists independently assessed endoscopic images for recurrence, and disagreements were resolved by a third reviewer. Hemorrhoid tissue biopsies were obtained using standard forceps. Samples were processed for hematoxylin-eosin and Masson's trichrome staining to evaluate vascular congestion and collagen deposition. Microvascular density and collagen-proportionate area were quantified using ImageJ software[17].

Statistical analysis

Continuous variables are presented as mean ± standard deviation (SD), and categorical variables as frequencies (%). Group comparisons were performed using the chi-square test or Wilcoxon rank-sum test, as appropriate.

Missing data were < 5% for all predictors. Twenty imputations were generated using chained equations under a missing-at-random assumption. Median follow-up was estimated by the reverse Kaplan-Meier method, and the distribution of censoring times was visualized to assess follow-up maturity.

All analyses were performed in R (version 4.5.1; R Foundation for Statistical Computing, Vienna, Austria) and SPSS (version 27.0; IBM Corp., Armonk, NY, United States). Relevant R packages are listed in *Supplementary Table S4*. Custom R scripts for data processing and figure generation are available from the corresponding authors upon reasonable request.

Statistical significance was defined as $P < 0.05$.

RESULTS

Patient characteristics and follow-up

A total of 504 patients with grade I internal hemorrhoids were prospectively enrolled across four centers. Twelve patients were excluded because of protocol-defined ineligibility, current anticoagulant/antiplatelet therapy, or inadequate retroflexed endoscopic visualization. Nine patients were lost to follow-up. Consequently, 483 patients completed the study protocol and were included in the final analysis (*Figure 1A*).

The cohort comprised 50.9% (246/483) male patients, with a median age of 52.5 years (52.5 ± 11.8). During the entire follow-up period, recurrence was documented in 23.8% (115/483) of patients. Mean age did not differ between the recurrence and non-recurrence groups (55.0 ± 21.0 vs 55.0 ± 18.0 years, P = 0.82). However, the proportion of male patients was significantly higher in the recurrence group than in the non-recurrence group (61.7% [71/115] vs 47.6% [175/368], P = 0.008). As expected, the observed follow-up duration was shorter in patients with recurrence because follow-up ended at relapse (27.4 ± 9.3 vs 61.0 ± 11.0 months, P < 0.0001) (*Table 1*).

The median potential follow-up for the entire cohort, calculated using the reverse Kaplan-Meier method, was 61.0 months (95%CI: 58.9-63.1). Among the 483 patients, 386 were censored. Censoring occurred predominantly after long-term follow-up, supporting follow-up maturity for recurrence assessment (*Supplementary Figure S2*). Kaplan-Meier estimates showed cumulative recurrence rates of 0.6% (3/483), 2.5% (12/483), 10.1% (49/483), and 20.0% (97/483) at 6, 12, 24, and 36 months, respectively. No severe procedure-related adverse events were observed during treatment or follow-up.

Endoscopic characteristics

At baseline, the recurrence group had a significantly greater number of hemorrhoids (P < 0.0001). Notably, 86.1% (99/115) of patients with recurrence presented with three or more hemorrhoids, compared with 52.7% (194/368) in the non-recurrence group. The recurrence group also exhibited a larger maximum hemorrhoid diameter (P < 0.0001) and a higher frequency of moderate-to-severe red color signs (grade 2-3: 38.3% vs 17.1%,

P < 0.0001). No significant intergroup differences were observed for mucosal erosion (P = 0.25) or dentate line injury (P = 0.26) (*Table 2*).

Endo-HRS model construction

The number of hemorrhoids, maximum diameter, and red color sign grade were strong independent predictors in multivariable modeling (all P < 0.0001). Although male sex did not reach conventional statistical significance in the final model (P = 0.08), it was retained because of clinical relevance and consistency with prior literature. All four variables satisfied the proportional hazards assumption (*Figure 2*).

The final model demonstrated good discrimination without evidence of multicollinearity (Supplementary Table S5). Time-dependent ROC analysis confirmed stable performance over time (Supplementary Figure S3). Calibration at 36 months showed a calibration-in-the-large of -2.51 and a calibration slope of 1.34, indicating mild systematic underestimation of absolute risk; nevertheless, predicted probabilities showed reasonable agreement with observed recurrence across risk deciles in internal validation (*Supplementary Figure S4*).

$$Risk\ Score = 1 \times Sex(male) + 4 \times Num + 11 \times Dia + 2 \times RCS$$

Regression coefficients were scaled by dividing each beta by the smallest coefficient (sex), multiplying by 2, and rounding to the nearest integer to generate a clinically usable score. Abbreviations: Sex, male = 1 and female = 0; Num, number of hemorrhoids; Dia, maximum hemorrhoid diameter (cm); RCS, red color sign grade (0-3). Patients were initially stratified into quartile-based risk groups (low, moderate, high, and very high; *Supplementary Table S6*). For clinical use, a simplified three-tier system (Endo-HRS groups A, B, and C) was derived (*Supplementary Table S7*). This simplified score showed good discrimination at 36 months (AUC = 0.86; Youden-optimized cutoff = 22.8; *Figure 3A*). Recurrence-free interval probability decreased progressively across these groups (*Figure 3B*), and individual recurrence risk could be estimated using a nomogram (*Figure 3C*).

A web-based Endo-HRS calculator was created to provide real-time risk estimation from the four model predictors. The tool automatically outputs the total score and corresponding risk category for individual patients. The interface is shown in *Supplementary Figure S5*.

External and multi-modal verification

External validation was performed in an independent cohort of 279 patients (*Figure 1B*). Endo-HRS demonstrated strong discrimination in this cohort (bootstrap-corrected C-index = 0.900, 95%CI: 0.862-0.933), with time-dependent AUCs exceeding 0.90 at 24, 36, and 48 months (*Figure 4A*). Calibration curves showed good agreement between predicted and observed recurrence (*Supplementary Figure S6*). Patients in group C had a significantly shorter recurrence-free interval than those in groups A and B ($P < 0.0001$; *Figure 4B*).

For multimodal verification, a subset of 40 participants was included. According to Endo-HRS, 9 patients were classified as group A, 24 as group B, and 7 as group C (*Supplementary Table S8*).

Endoscopic imaging analysis showed that higher-risk groups exhibited more prominent red color signs, a greater number of hemorrhoids, and larger diameters (*Figure 5A-C*), indicating that Endo-HRS classification was consistent with endoscopic severity and clinical outcomes ($P < 0.0001$).

Histopathological analysis further supported the model. Patients in the Endo-HRS C group showed marked dilation and congestion of submucosal venules (*Figure 5D-F*), consistent with a greater clinical tendency toward bleeding. Masson's trichrome staining revealed denser collagen deposition in higher-risk groups (*Figure 5G-I*). The collagen proportionate area was 14.6-fold and 2.6-fold higher in group C than in groups A and B, respectively (*Supplementary Table S9 and Figure S7*). These findings suggest that recurrence risk may be driven by both vascular abnormalities and aberrant collagen deposition.

DISCUSSION

To our knowledge, this is the first prospective study to systematically evaluate long-term recurrence after 1% polidocanol foam sclerotherapy for grade I internal hemorrhoids while developing a clinically applicable prediction model based on objective endoscopic features. Building on prior work showing the efficacy and safety of endoscopic polidocanol-based therapy[10-12, 18], the present study addresses an important unmet need: individualized recurrence risk stratification.

Recurrence increased progressively over time, with cumulative rates of 2.5%, 10.1%, and 20.0% at 12, 24, and 36 months, respectively. These findings are broadly consistent with prior reports[6,19], although previous studies largely used 3% polidocanol and focused on grade II-III disease[6,19-22]. In our cohort, 1% polidocanol foam maintained durable efficacy in grade I disease, and no severe procedure-related adverse events were recorded.

Despite the substantial clinical burden of hemorrhoidal disease[23], dedicated work on objective risk stratification remains limited. Traditional classifications such as Goligher's system emphasize prolapse and do not capture recurrence biology adequately[24]. Even more recent symptom-oriented systems remain predominantly descriptive[25-28]. In contrast, our model integrates objective endoscopic indicators - number of hemorrhoids, maximum diameter, and red color sign grade - with sex to generate a practical recurrence score.

Male sex was retained in the final model despite borderline statistical significance because its effect estimate was directionally consistent, clinically plausible, and did not impair overall model performance. This decision favors bedside usability and clinical interpretability rather than purely automated variable selection.

During development, patients were first stratified into four score-based categories, but a four-tier structure is cumbersome in routine practice. The simplified three-group Endo-HRS classification is easier to apply and may support differentiated surveillance strategies: patients with low scores may avoid unnecessarily intensive endoscopic

follow-up, whereas those with high scores may benefit from closer surveillance and earlier retreatment consideration.

A notable strength of the study is the multimodal verification strategy. Endoscopic images in higher-risk groups showed larger hemorrhoids and more prominent vascular changes, whereas histopathology demonstrated venous congestion and increased collagen deposition. These observations complement emerging evidence that vascular remodeling and extracellular matrix alteration may be involved in hemorrhoid pathophysiology and recurrence[29-32]. Although exploratory, the biologic coherence between endoscopic phenotype and tissue pathology strengthens the face validity of Endo-HRS.

This study has limitations. First, the model was developed in Chinese patients with grade I internal hemorrhoids treated with foam sclerotherapy, which may limit generalizability to other populations, hemorrhoid grades, or treatment modalities. Second, additional external validation in larger and more diverse cohorts is required. Third, although endoscopic variables are more objective than symptom-based descriptors, interobserver variability remains possible and may require standardized training or future AI-assisted support. Finally, the mechanistic implications drawn from histology remain hypothesis-generating and require further confirmation.

CONCLUSION

Endo-HRS is an endoscopy-based model for predicting recurrence after foam sclerotherapy in grade I internal hemorrhoids. It offers a practical and externally validated tool for risk stratification and may support individualized follow-up and treatment planning.

ACKNOWLEDGEMENTS

The authors thank all patients for participating and for permitting the use of their treatment and follow-up data. The authors also thank the medical statistics team of

Xinhua Hospital for methodological support. All authors take responsibility for the integrity of the work.

REFERENCES

1 **Tomasicchio G**, Martines G, Lantone G, Dibra R, Trigiante G, De Fazio M, Picciariello A, Altomare DF, Rinaldi M. Safety and Effectiveness of Tailored Hemorrhoidectomy in Outpatients Setting. Front Surg 2021; **8**: 708051 [PMID: 34485375 PMCID: PMC8415450 DOI: 10.3389/fsurg.2021.708051]

2 **Lee KC**, Liu CC, Hu WH, Lu CC, Lin SE, Chen HH. Risk of delayed bleeding after hemorrhoidectomy. Int J Colorectal Dis 2019; **34(2)**: 247-253 [PMID: 30357461 PMCID: PMC6331745 DOI: 10.1007/s00384-018-3176-6]

3 **Sikakulya FK**, Ssebuufu R, Okedi XF, Baluku M, Lule H, Kiyaka SM, Kyamanywa P. Pain assessment following open hemorrhoidectomy under local anesthesia versus saddle block: a multicenter randomized controlled trial. BMC Surg 2023; **23(1)**: 124 [PMID: 37173653 PMCID: PMC10182622 DOI: 10.1186/s12893-023-02030-6]

4 **Lauricella S**, Palmisano D, Brucchi F, Agoglitta D, Fiume M, Bottero L, Faillace G. Long-term results and quality of life after stapled hemorrhoidopexy vs Doppler-guided HAL-RAR: a propensity score matching analysis. Int J Colorectal Dis 2024; **39(1)**: 30 [PMID: 38386081 PMCID: PMC10884154 DOI: 10.1007/s00384-024-04603-0]

5 **Zhang FM**, Wu KC, Li JN, Wang X, He XX, Wan R, Chen SY. Rationale, new anus positioning methods, and updated protocols: Expert recommendations on cap-assisted endoscopic sclerotherapy for hemorrhoids from China Gut Conference. Chin Med J (Engl) 2021; **134(22)**: 2675-2677 [PMID: 34711720 PMCID: PMC8631410 DOI: 10.1097/cm9.0000000000001836]

6 **Salgueiro P**, Garrido M, Santos RG, Pedroto I, Castro-Poças FM. Polidocanol Foam Sclerotherapy Versus Rubber Band Ligation in Hemorrhoidal Disease Grades I/II/III: Randomized Trial. Dis Colon Rectum 2022; **65(7)**: e718-e727 [PMID: 34840294 DOI: 10.1097/dcr.0000000000002117]

7 **Gallo G**, Grossi U, De Simone V, Picciariello A, Diaco E, Fan P, He H, Li J, Lin H, La Torre M, Laforgia R, Lobascio P, Ma H, Pata F, Perinotti R, De Parades V, Pozzo M, Realis Luc A, Salgueiro P, Skowronski A, Sun P, Trompetto M, Tutino R, Wang C, Wang Z, Wang Z, Wu J, Zhang Y, Zhao S, Zeng X, Fernandes V, Moser KH, Ren D, Sileri P, Gravante G. Real-world use of polidocanol foam sclerotherapy for hemorrhoidal disease: insights from an international survey and systematic review with clinical practice recommendations. Updates Surg 2025; **77(5)**: 1439-1450 [PMID: 40481245 PMCID: PMC12420758 DOI: 10.1007/s13304-025-02258-2]

8 **Wu X**, Wen Q, Cui B, Liu Y, Zhong M, Yuan Y, Wu L, Zhang X, Hu Y, Lv M, Wu Q, He S, Jin Y, Tian S, Wan R, Wang X, Xu L, Bai J, Huang G, Ji G, Zhang F. Cap-assisted endoscopic sclerotherapy for internal hemorrhoids: technique protocol and study design for a multi-center randomized controlled trial. Ther Adv Gastrointest Endosc 2020; **13**: 2631774520925636 [PMID: 32551439 PMCID: PMC7278306 DOI: 10.1177/2631774520925636]

9 **Takada S**, Tsunoda A, Takahashi T, Kusanagi H. Early postoperative outcomes of a novel nonexcisional technique using aluminum potassium sulfate and tannic acid sclerotherapy with mucopexy on patients with grade III hemorrhoids. Ann Coloproctol 2022; **38(4)**: 290-296 [PMID: 34724727 PMCID: PMC9441537 DOI: 10.3393/ac.2020.00920.0131]

10 **Qu CY**, Zhang FY, Wang W, Gao FY, Lin WL, Zhang H, Chen GY, Zhang Y, Li MM, Li ZH, Cai MH, Xu LM, Shen F. Endoscopic polidocanol foam sclerobanding for the treatment of grade II-III internal hemorrhoids: A prospective, multi-center, randomized study. World J Gastroenterol 2024; **30(27)**: 3326-3335 [PMID: 39086750 PMCID: PMC11287420 DOI: 10.3748/wjg.v30.i27.3326]

11 **Rao AG**, Nashwan AJ. Redefining hemorrhoid therapy with endoscopic polidocanol foam sclerobanding. World J Gastroenterol 2024; **30(36)**: 4021-4024 [PMID: 39351248 PMCID: PMC11439121 DOI: 10.3748/wjg.v30.i36.4021]

12 **Mou AN**, Wang YT. Endoscopic polidocanol foam sclerobanding for treatment of internal hemorrhoids: A novel outpatient procedure. World J Gastroenterol 2024; **30(42)**: 4583-4586 [PMID: 39563748 PMCID: PMC11572621 DOI: 10.3748/wjg.v30.i42.4583]
13 **Collins GS**, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. Bmj 2024; **385**: e078378 [PMID: 38626948 PMCID: PMC11019967 DOI: 10.1136/bmj-2023-078378]
14 World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama 2013; **310(20)**: 2191-2194 [PMID: 24141714 DOI: 10.1001/jama.2013.281053]
15 **Hassan C**, East J, Radaelli F, Spada C, Benamouzig R, Bisschops R, Bretthauer M, Dekker E, Dinis-Ribeiro M, Ferlitsch M, Fuccio L, Awadie H, Gralnek I, Jover R, Kaminski MF, Pellisé M, Triantafyllou K, Vanella G, Mangas-Sanjuan C, Frazzoni L, Van Hooft JE, Dumonceau JM. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy 2019; **51(8)**: 775-794 [PMID: 31295746 DOI: 10.1055/a-0959-0505]
16 Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg 2001; **27(1)**: 58-60 [PMID: 11231246]
17 **Schroeder AB**, Dobson ETA, Rueden CT, Tomancak P, Jug F, Eliceiri KW. The ImageJ ecosystem: Open-source software for image visualization, processing, and analysis. Protein Sci 2021; **30(1)**: 234-249 [PMID: 33166005 PMCID: PMC7737784 DOI: 10.1002/pro.3993]
18 **Gravante G**. Sclerotherapy for hemorrhoidal disease: Recent evolutions of an oldies goldy. World J Gastroenterol 2025; **31(8)**: 98704 [PMID: 40062327 PMCID: PMC11886522 DOI: 10.3748/wjg.v31.i8.98704]

19 **Gallo G**, Pietroletti R, Novelli E, Sturiale A, Tutino R, Lobascio P, Laforgia R, Moggia E, Pozzo M, Roveroni M, Bianco V, Luc AR, Giuliani A, Diaco E, Naldini G, Trompetto M, Perinotti R, Sammarco G. A multicentre, open-label, single-arm phase II trial of the efficacy and safety of sclerotherapy using 3% polidocanol foam to treat second-degree haemorrhoids (SCLEROFOAM). Tech Coloproctol 2022; **26(8)**: 627-636 [PMID: 35334004 PMCID: PMC8949823 DOI: 10.1007/s10151-022-02609-w]
20 **Lobascio P**, Laforgia R, Novelli E, Perrone F, Di Salvo M, Pezzolla A, Trompetto M, Gallo G. Short-Term Results of Sclerotherapy with 3% Polidocanol Foam for Symptomatic Second- and Third-Degree Hemorrhoidal Disease. J Invest Surg 2021; **34(10)**: 1059-1065 [PMID: 32290709 DOI: 10.1080/08941939.2020.1745964]
21 **Neves S**, Falcão D, Povo A, Castro-Poças F, Oliveira J, Salgueiro P. 3% polidocanol foam sclerotherapy versus hemorrhoidal artery ligation with recto anal repair in hemorrhoidal disease grades II-III: a randomized, pilot trial. Rev Esp Enferm Dig 2023; **115(3)**: 115-120 [PMID: 35638762 DOI: 10.17235/reed.2022.8568/2022]
22 **Gallo G**, Picciariello A, Pietroletti R, Novelli E, Sturiale A, Tutino R, Laforgia R, Moggia E, Pozzo M, Roveroni M, Bianco V, Realis Luc A, Giuliani A, Diaco E, Naldini G, Trompetto M, Perinotti R, D'Andrea V, Lobascio P. Sclerotherapy with 3% polidocanol foam to treat second-degree haemorrhoidal disease: Three-year follow-up of a multicentre, single arm, IDEAL phase 2b trial. Colorectal Dis 2023; **25(3)**: 386-395 [PMID: 36268758 DOI: 10.1111/codi.16380]
23 **Cosman BC**. Piles of Money: "Hemorrhoids" Are a Billion-Dollar Industry. Am J Gastroenterol 2019; **114(5)**: 716-717 [PMID: 30998519 DOI: 10.14309/ajg.0000000000000234]
24 **Dekker L**, Han-Geurts IJM, Grossi U, Gallo G, Veldkamp R. Is the Goligher classification a valid tool in clinical practice and research for hemorrhoidal disease? Tech Coloproctol 2022; **26(5)**: 387-392 [PMID: 35141793 PMCID: PMC9018630 DOI: 10.1007/s10151-022-02591-3]
25 **Margetis N**. Pathophysiology of internal hemorrhoids. Ann Gastroenterol 2019; **32(3)**: 264-272 [PMID: 31040623 PMCID: PMC6479658 DOI: 10.20524/aog.2019.0355]

26 **Sandler RS**, Peery AF. Rethinking What We Know About Hemorrhoids. Clin Gastroenterol Hepatol 2019; **17(1)**: 8-15 [PMID: 29601902 PMCID: PMC7075634 DOI: 10.1016/j.cgh.2018.03.020]
27 **Lohsiriwat V**, Sheikh P, Bandolon R, Ren DL, Roslani AC, Schaible K, Freitag A, Martin M, Yaltirik P, Godeberge P. Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review. Adv Ther 2023; **40(1)**: 117-132 [PMID: 36331754 PMCID: PMC9859842 DOI: 10.1007/s12325-022-02351-7]
28 **Rørvik HD**, Styr K, Ilum L, McKinstry GL, Dragesund T, Campos AH, Brandstrup B, Olaison G. Hemorrhoidal Disease Symptom Score and Short Health ScaleHD: New Tools to Evaluate Symptoms and Health-Related Quality of Life in Hemorrhoidal Disease. Dis Colon Rectum 2019; **62(3)**: 333-342 [PMID: 30451751 DOI: 10.1097/dcr.0000000000001234]
29 **Zheng T**, Ellinghaus D, Juzenas S, Cossais F, Burmeister G, Mayr G, Jørgensen IF, Teder-Laving M, Skogholt AH, Chen S, Strege PR, Ito G, Banasik K, Becker T, Bokelmann F, Brunak S, Buch S, Clausnitzer H, Datz C, Degenhardt F, Doniec M, Erikstrup C, Esko T, Forster M, Frey N, Fritsche LG, Gabrielsen ME, Gräßle T, Gsur A, Gross J, Hampe J, Hendricks A, Hinz S, Hveem K, Jongen J, Junker R, Karlsen TH, Hemmrich-Stanisak G, Kruis W, Kupcinskas J, Laubert T, Rosenstiel PC, Röcken C, Laudes M, Leendertz FH, Lieb W, Limperger V, Margetis N, Mätz-Rensing K, Németh CG, Ness-Jensen E, Nowak-Göttl U, Pandit A, Pedersen OB, Peleikis HG, Peuker K, Rodriguez CL, Rühlemann MC, Schniewind B, Schulzky M, Skieceviciene J, Tepel J, Thomas L, Uellendahl-Werth F, Ullum H, Vogel I, Volzke H, von Fersen L, von Schönfels W, Vanderwerff B, Wilking J, Wittig M, Zeissig S, Zobel M, Zawistowski M, Vacic V, Sazonova O, Noblin ES, Farrugia G, Beyder A, Wedel T, Kahlke V, Schafmayer C, D'Amato M, Franke A. Genome-wide analysis of 944 133 individuals provides insights into the etiology of haemorrhoidal disease. Gut 2021; **70(8)**: 1538-1549 [PMID: 33888516 PMCID: PMC8292596 DOI: 10.1136/gutjnl-2020-323868]
30 **Sninsky JA**, Galanko J, Sandler RS, Peery AF. Diverticulosis Is Associated With Internal Hemorrhoids on Colonoscopy: Possible Clues to Etiology. Clin Gastroenterol

Hepatol 2023; **21(4)**: 1097-1099.e1093 [PMID: 35176499 PMCID: PMC9375803 DOI: 10.1016/j.cgh.2022.02.020]

31 **De Martino D**, Bravo-Cordero JJ. Collagens in Cancer: Structural Regulators and Guardians of Cancer Progression. Cancer Res 2023; **83(9)**: 1386-1392 [PMID: 36638361 PMCID: PMC10159947 DOI: 10.1158/0008-5472.Can-22-2034]

32 **Fu Y**, Zhou Y, Wang K, Li Z, Kong W. Extracellular Matrix Interactome in Modulating Vascular Homeostasis and Remodeling. Circ Res 2024; **134(7)**: 931-949 [PMID: 38547250 DOI: 10.1161/circresaha.123.324055]

Footnotes

Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Approval No. XHEC-C-2020-003-1) and by the ethics committees of the participating centers.

Informed consent statement: All study participants or their legal guardians provided informed written consent prior to study enrollment. Due to the large sample size, only a representative de-identified informed consent form is provided. All original signed informed consent forms are securely archived at our institution and are available upon request.

Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.

Data sharing statement: The deidentified data that support the findings of this study are available from the corresponding authors upon reasonable request, subject to institutional and ethical approval.

STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

Figures and Tables

Graphical Abstract



Graphical Abstract. Patients with Goligher's grade I internal hemorrhoids receiving foam sclerotherapy were analyzed for endoscopic and clinical features. The Endoscopic Hemorrhoid Recurrence Score (Endo-HRS) was developed and externally validated with independent cohorts and endoscopic/histopathological correlation. Endo-HRS provides individualized recurrence risk stratification after endoscopic treatment to guide clinical management.

Figure 1



Figure 1. Study cohort flowchart. A. Development cohort. B. External validation cohort.

Figure 2



Figure 2. Forest plot of variables in the prediction model.

Figure 3



Figure 3. Model performance and clinical application of the Endo-HRS. A. Time-dependent receiver operating characteristic (ROC) curve for predicting 36-month recurrence. The bronze, green, and blue dots represent rule-in, Youden-optimized, and rule-out thresholds, respectively. B. Kaplan-Meier curves of recurrence-free interval stratified by Endo-HRS groups A (blue), B (green), and C (bronze). C. Nomogram for predicting the individual probability of recurrence at 36 months. Abbreviations: AUC, area under curve.

Figure 4



Figure 4. External validation of the Endo-HRS model. A. Time-dependent receiver operating characteristic (ROC) curves for recurrence prediction at 24 (bronze), 36 (green), and 48 (blue) months. B. Kaplan-Meier recurrence-free interval curves for Endo-HRS groups A (blue), B (green), and C (bronze).

Figure 5



Figure 5. Multi-modal verification of Endo-HRS model. A-C. Endoscopic images of Endo-HRS A, B, and C groups, respectively (Black arrows: hemorrhoids; White arrows: red color signs). D-F. H&E staining of Endo-HRS A, B, and C groups, respectively (20×, scale bar = 50 μm) (Black triangles: enlarged blood vessels). G-I. Masson staining of Endo-HRS A, B, and C groups, respectively (20×, scale bar = 50 μm).

Table 1. Baseline clinical characteristics of patients in recurrence and no recurrence groups.

Variable	Recurrence (n = 115)	No recurrence (n = 368)	P value
Age, years (mean ± SD)	55.0 ± 21.0	55.0 ± 18.0	0.82
Male sex, n (%)	71 (61.7)	175 (47.6)	0.008
Observed follow-up, months (mean ± SD)	27.4 ± 9.3	61.0 ± 11.0	<0.0001

Median potential follow-up for the entire cohort (reverse Kaplan-Meier): 61.0 months (95%CI: 58.9-63.1).

Table 2. Endoscopic characteristics of patients in recurrence and no recurrence groups.

A. Number of hemorrhoids and maximum hemorrhoid diameter

Group	Number of hemorrhoids					Maximum hemorrhoid diameter		
	1	**2**	**3**	**4**	**5**	**<0.8 cm**	**0.8 cm <= diameter < 1.2 cm**	**>=1.2 cm**
Recurrence (n = 115)	0 (0.0%)	16 (13.9%)	72 (62.6%)	26 (22.6%)	1 (0.9%)	4 (3.5%)	71 (61.7%)	40 (34.8%)
No recurrence (n = 368)	31 (8.4%)	143 (38.9%)	183 (49.7%)	11 (3.0%)	0 (0.0%)	126 (34.2%)	202 (54.9%)	40 (10.9%)

Overall distribution P value: number of hemorrhoids, <0.0001; maximum hemorrhoid diameter, <0.0001.

B. Red color sign, mucosal erosion, and dentate line injury

Group	Grade of red color sign				Mucosal erosion		Dentate line injury		
	0	**1**	**2**	**3**	**No**	**Yes**	**0**	**<0.5 cm**	**>=0.5 cm**
Recurrence (n = 115)	5 (4.3%)	66 (57.4%)	31 (27.0%)	13 (11.3%)	105 (91.3%)	10 (8.7%)	101 (87.8%)	11 (9.6%)	3 (2.6%)
No recurrence (n = 368)	153 (41.6%)	152 (41.3%)	63 (17.1%)	0 (0.0%)	347 (94.3%)	21 (5.7%)	336 (91.3%)	26 (7.1%)	6 (1.6%)

Overall distribution P value: red color sign, <0.0001; mucosal erosion, 0.25; dentate line injury, 0.26


Internal hemorrhoids
Bleeding
Pain
Age
Sex
Baseline characteristics
Model construction
Endo-HRS Model
Endo-HRS C
C
B
Endo-HRS B
Endo-HRS A
A
Follow-up
External cohort
Endo-images
Patho-images
Multi-modal verification
Number
Diameter
Red color sign
Mucosa
Dentate line
Endoscopic characteristics
Liquid
Polidocanol
Foam
Endoscopic foam sclerotherapy


A
Development cohort
Assessed for eligibility
(n=504)
Excluded (n=12)
- Over the age limit: n=3
- Taking oral anticoagulant or antiplatelet drugs: n=8
- Unable to tolerate endoscopic treatment: n=1
Included in prospective cohort
(n=492)
Follow-up
- Completed (n=483)
- Lost (n=9)
Included in final analysis
(n=483)
B
External validation cohort
Assessed for eligibility
(n=291)
Excluded (n=5)
- Over the age limit: n=3
- Taking oral anticoagulant or antiplatelet drugs: n=2
Included in prospective cohort
(n=286)
Follow-up
- Completed (n=279)
- Lost (n=7)
Included in final analysis
(n=279)


Variable
HR
(95% CI)
Sex (male)
1.32
(0.90−1.92)
Number of
hemorrhoids
3.39
(2.44−4.72)
Maximum hemorrhoid
diameter
22.94
(6.97−75.52)
Grade of
red color sign
1.67
(1.24−2.25)
1.0
2.0
4.0
8.0
16.0
32.0
64.0
Hazard Ratio (95% CI)


A
Time-dependent ROC curves at 36 months
Sensitivity
1-Specificity
Youden
Rule-out
Rule-in
0.0
0.2
0.4
0.6
0.8
1.0


B
Risk Group
Endo-HRS Group A
Endo-HRS Group B
Endo-HRS Group C
Recurrence-free Internal
Follow-up Time (months)
p < 0.0001
1.00
0.75
0.50
0.25
0.00
0
20
40
60
80


C
Points
0 10 20 30 40 50 60 70 80 90
Sex
male
female
Number of hemorrhoids
2 4
1 3 5
Maximum hemorrhoid diameter
0.6 0.9 1.2
0.5 0.8 1 1.3
Grade of red color sign
2 4
1 3
Total points
0 20 40 60 80 120 160
36-month Recurrence Probability
90 70 50 30 10


A
Sensitivity
1-Specificity
0.0
0.2
0.4
0.6
0.8
1.0
24 mo, AUC=0.90
36 mo, AUC=0.94
48 mo, AUC=0.95
B
Risk Group
Endo-HRS A
Endo-HRS B
Endo-HRS C
Recurrence-free Probability
1.00
0.75
0.50
0.25
0.00
0
20
40
60
Follow-up Time (months)
p < 0.0001


A
B
C
D
E
F
G
H
I